Generics
Mylan unveils generic Suboxone Sublingual Film for treating opioid dependence
25 February 2019 -

Pharmaceutical company Mylan NV (NASDAQ:MYL) revealed on Friday the availability of Buprenorphine and Naloxone Sublingual Film in 8 mg/2 mg and 12 mg/3 mg in the US.

The company added that Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg is the generic version of Indivior's Suboxone Sublingual Film.

According to the company, the US Food and Drug Administration (FDA) approved Buprenorphine and Naloxone Sublingual Film is indicated for the treatment of opioid dependence under a complete treatment plan that includes counselling and psycho-social support. Its prescription is limited to healthcare providers who meet certain qualifying requirements including notification to Department of Health and Human services of their intent to prescribe this product.

For the 12 months ending 31 December 2018, the US sales for the company's Buprenorphine and Naloxone Sublingual Film in 8 mg/2 mg and 12 mg/3 mg were approximately USD1.87bn, according to IQVIA.

Login
Username:

Password: